Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by prophetoffactzon Jan 10, 2023 1:29pm
119 Views
Post# 35213836

RE:RE:RE:RE:RE:RE:RE:Saltarelli is in the catbird seat...

RE:RE:RE:RE:RE:RE:RE:Saltarelli is in the catbird seat..."Yes, shareholders did demand that Rathjen avoid dilution. That was 4 years ago. Now, with 6% ownership on the horizon I see 94% dilution, with total loss of control.So, are you saying, poof, that Rathjen acted on shareholder wishes to do this?"

Being severely undercapitalized can boomerang bigtime. Maybe Rathjen should have said that she will only agree to take the job if shareholders put $15 million on the balance sheet to do something with. Then shareholders would have been forced to deal with the need to properly capitalize this company from the beginning. Giving her handcuffs instead of a properly financed company and telling her to avoid dilution into the worst biotech market in history and into relationships that demand secrecy was a big risk. Loading up on debt for biotech is also very risky given biotech's burn rate and eternal dependence on fickle capital markets; especially into the worst biotech market in history. Given BTI's debt it was leveraged to the crisis in biotech. It further had to pay Ladenberg Thalmann to help with rescue in any way possible.This company has been in a permanent state of financial emergency for many, many years. Biodexa put this company on a strong financial footing once and for all and gives it a cash runway to catalysts. Rathjenshould have demanded BTI be put on a strong financial footing to start. 
<< Previous
Bullboard Posts
Next >>